Clinical Trials Logo

ITCH clinical trials

View clinical trials related to ITCH.

Filter by:

NCT ID: NCT04289038 Completed - Pruritus Clinical Trials

The Efficacy of VR and AR on Pruritus

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The research will be conducted randomly in order to determine the effect of VR and AR on pruritus symptom.

NCT ID: NCT04115462 Completed - Itch Clinical Trials

A Relation of Morphine-induced Itch and Pain Processing

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

In This experiment, the investigators would like to test the two following hypotheses regarding the mechanisms by which opioids cause itch: 1. Opioids cause itch by a spinal disinhibition mechanism (central nervous system (CNS) effect). 2. Opioids cause itch through a mast cell-destabilizing effect leading to release of histamine and tryptase in the skin where itch is evoked (peripheral mechanism).

NCT ID: NCT04076865 Completed - Lidocaine Clinical Trials

Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch

Start date: October 15, 2019
Phase: N/A
Study type: Interventional

In this experiment, the investigators would like to study if the repeated application of local cuaneous anaesthetic EMLA cream will reduce itch induced by small needles from the plant mucuna pruriens (also known as cowhage) and histamine (an itch proving substance formed in the body).

NCT ID: NCT03928223 Completed - Pruritus Clinical Trials

The Color of Itch; Itch Modification by Color Viewing

Start date: March 1, 2017
Phase:
Study type: Observational

Itch is the commonest skin-related symptom. There is increasing evidence that itch can be influenced by visual cues. The impact of colors on itch has not yet been studied. This study investigates Itch modification by color viewing and whether patients can match or counteract their itch with a color.

NCT ID: NCT03928093 Completed - Pain, Neuropathic Clinical Trials

Pregabalin Treatment for RDEB Pain and Itch

Start date: August 7, 2019
Phase: Phase 3
Study type: Interventional

Recessive dystrophic epidermolysis bullosa (RDEB) patients' quality of life is severely affected by neuropathic pain and itch, which have recently been demonstrated to be secondary to skin small fiber neuropathy. To date, there is no evidence on what the best agent is to control these symptoms. Based on the anecdotal data and safety profile, the investigators believe that pregabalin is a therapeutic agent that will be effective and safe in this population. The investigators propose to conduct a blinded study, using pregabalin versus placebo in which each patient serves as its own control (cross-over design). This is a feasibility study that will provide preliminary data on efficacy and safety of pregabalin in RDEB patients with neuropathic pain and itch and gather much needed data (dosage, titration schedule, outcome measures, etc) to inform the design of a larger cohort, controlled, multicenter trial.

NCT ID: NCT03901443 Completed - Itch Clinical Trials

Survey on Itch in Outpatients of a University Clinic

Start date: December 9, 2015
Phase:
Study type: Observational

This study is to investigate the pruriception (i.e. the perception of the character and intensity of itch), the impact of itch on quality of life, the response to itch and the subjective efficacy and preferences of the different treatment options among patients with different skin diseases. Better insights into these aspects might help to optimize itch treatment in clinical Settings.

NCT ID: NCT03576053 Completed - Itch Clinical Trials

A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this human experimental study is to evaluate the pattern of itch intensity over time in response to strong, short-term heat stimulation in two different models of histamine and cowhage-induced itch. Moreover, the purpose is to evaluate the effect of mild pre-heating of the skin in human experimental models of histamine, cowhage and serotonin. Finally, we want to investigate the effect of short-term intense heat stimulation on previously anesthetized skin.

NCT ID: NCT03239106 Completed - Itch Clinical Trials

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.

NCT ID: NCT02075632 Completed - Psoriasis Clinical Trials

Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream

Start date: September 2006
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.

NCT ID: NCT01683552 Completed - ITCH Clinical Trials

Aprepitant in the Management of Biological Therapies-related Severe Pruritus

AprepIt
Start date: September 2010
Phase: Phase 2
Study type: Interventional

Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the effects of Aprepitant, a neurokinin receptor inhibitor, in managing biological therapy-induced pruritus.